Recent News

• 08.04.2026 - Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
• 07.21.2026 - Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
• 06.11.2026 - Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
• 05.18.2026 - Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
• 05.01.2026 - Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
• 04.29.2026 - Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
• 03.03.2026 - Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
• 01.20.2026 - Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
• 11.06.2025 - Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
• 11.03.2025 - Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Recent Filings

• 07.21.2026 - 8-K Current report
• 07.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.08.2026 - ARS Annual Report to Security Holders
• 06.08.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.08.2026 - DEF 14A Other definitive proxy statements
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - PRE 14A Other preliminary proxy statements
• 05.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors